Routine shallow-coverage Whole Genome Sequencing of Cervical Smears to See if Ovarian Cancer is Found Earlier

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects tumour and healthy tissue samples from patients with high-grade serous ovarian cancer who are scheduled for initial surgery. A liquid-based cervical smear is taken as part of routine care to screen for concomitant cervical cancer, and DNA is analyzed for genomic instability using whole-genome sequencing. The study aims to see if tumor-derived signals in cervical samples can indicate ovarian cancer origin noninvasively. Analyses include quantifying tumor material, DNA extraction and sequencing, and standard histopathology for confirmation. Interventions are not tested; the study observes and analyzes diagnostic material from the care pathway.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients :

* With high-grade serous ovarian carcinoma treated at the IUCT-O
* For whom initial surgery (diagnostic or cytoreductive) is planned

Exclusion Criteria:

Patients with :

* Concurrent endometrial or cervical cancer
* History of cancer within the last two years
* History of gynaecological cancer
* History of salpingectomy, hysterectomy or trachelectomy (removal of the cervix)

Where it's running

• Institut Claudius Regaud
  Toulouse, France Recruiting

Study contacts

• Study coordinator: Giulio Ricotta, Dr
• Email: ricotta.giulio@iuct-oncopole.fr
• Phone: +33(0)5 31 15 50 50

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FRα expression in high-grade serous ovarian cancer (FRα positive)

  A retrospective study in Greece will test how often Folate Receptor Alpha is present in tumor samples from adults diagnosed with high-grade serous ovarian cancer.

  Recruiting Hellenic Cooperative Oncology Group · Athens · NCT07889843

• Risk of cervical cancer after HPV detection in healthy women

  This study tests how likely it is for cervical cancer to develop after different HPV detection patterns in healthy women who undergo HPV-based screening.

  Recruiting Karolinska Institutet · Stockholm · NCT07850128

• HPV self-sampling in the ED to screen under-screened women

  This study tests whether giving an HPV self-sampling kit in the emergency department can help under-screened women get screened for cervical cancer and find those with HPV to guide follow-up care.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey and 1 other locations · NCT07657104

• Low-cost HPV test that gives same-day results and treatment in women 30-59

  A low-cost HPV test done on the same day as a self-collected sample is being tested to see if it can reliably screen for cervical cancer and enable immediate treatment in women aged 30-59 in San Salvador.

  Recruiting The Cleveland Clinic · San Salvador, Oriente · NCT07538050

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• Self-sampling HPV screening offered in the emergency department

  This project tests whether offering HPV self-sampling in the emergency department helps more people aged 30–65 with a cervix get screened for cervical cancer.

  Recruiting University of Rochester · Rochester, New York · NCT07345897

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.